Back to top

Analyst Blog

Ariad Pharmaceuticals, Inc. (ARIA - Snapshot Report) recently announced the commencement of an open-label, multicenter phase II trial of Iclusig (ponatinib) in patients suffering from metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

The study will evaluate Iclusig’s efficacy and safety in patients who have failed at least one tyrosine kinase inhibitor (TKI) therapy.

Iclusig, a TKI which was launched in Jan 2013, is currently marketed in the US by Ariad for treating adults suffering from chronic, accelerated or blast phase chronic myeloid leukemia, and Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to TKI therapy.

Ariad recorded Iclusig sales of $6.4 million in the first quarter of 2013. The company is currently looking to gain approval for Iclusig in the EU. Ariad received a positive opinion for Iclusig from the Committee for Human Medicinal Products (CHMP) in Mar 2013 – we believe approval will come shortly. Ariad expects to launch Iclusig in the EU by Jul 1, 2013.

While Ariad has submitted a marketing application in Switzerland, the company anticipates regulatory submissions in Canada and Australia in the third quarter of 2013 and in Japan in mid 2014.

According to the American Cancer Society, about 4,000-5,000 GIST cases occur in the US every year. Currently approved treatments include Pfizer Inc.’s (PFE - Analyst Report) Sutent and Novartis’ (NVS - Analyst Report) Gleevec among others. Earlier this year, Stivarga gained FDA approval for GIST.

Ariad currently carries a Zacks Rank # 3 (Hold). At present, Jazz Pharmaceuticals Public Limited Company (JAZZ - Analyst Report) looks well positioned with a Zacks Rank # 1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%